PNEUMOVAX 23 -(5-DOSE) 25 MCG / 0.5 ML
PNEUMOCOCCAL VACCINE POLYVALENT : 25 MCG / 0.5 ML · DIN 02240632 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is PNEUMOVAX 23 -(5-DOSE)?
PNEUMOVAX 23 -(5-DOSE) 25 MCG / 0.5 ML contains PNEUMOCOCCAL VACCINE POLYVALENT : 25 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02240632, held by MERCK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 09-Feb-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PNEUMOVAX 23 -(5-DOSE) used for?
Vaccination against pneumococcal disease caused by the 23 serotypes in the vaccine. Recommended for adults ≥ 50, and high-risk individuals ≥ 2 years (chronic disease, immunocompromised, asplenia).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02240632 |
|---|---|
| Brand name | PNEUMOVAX 23 -(5-DOSE) |
| Generic / active ingredient | PNEUMOCOCCAL VACCINE POLYVALENT : 25 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 25 MCG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED |
| AHFS class | 92:01.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Feb-2007 |
How is it administered?
Single 0.5 mL dose administered subcutaneously or intramuscularly (preferably deltoid or lateral mid-thigh). Do not inject intravenously or intradermally.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2-8°C (Refrigerate). [Note: Standard vaccine storage; though specific text was truncated, typical for this product].
How is it supplied?
1 x 0.5 mL vial or 10 x 0.5 mL vials.
Contraindications
Hypersensitivity to any component of the vaccine. Anaphylactic reaction to polysaccharide pneumococcal vaccine is a contraindication to re-immunization.
Warnings and precautions
Epinephrine must be available for anaphylaxis. Use caution in severely compromised cardio/pulmonary function. Delay in case of febrile illness. Not for prevention of CSF leak-related meningitis.
What can be used instead?
Other Canadian products sharing ATC code J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAPVAXIVE | 4 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | MARKETED | DIN 02549891 |
| PREVNAR 20 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02527049 |
| VAXNEUVANCE | 30 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | DIN 02522403 |
| PNEUMO 23 | 25 MCG / 0.5 ML | LIQUID | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02231259 |
| PNEUMOVAX 23 | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00431648 |
| PNU-IMUNE 23 | 25 MCG / 0.5 ML | LIQUID | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | CANCELLED POST MARKET | DIN 02230175 |
| PREVNAR | 20 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02244081 |
| PREVNAR 13 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02335204 |
| SYNFLORIX | 3 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02320541 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.